More then two EMA oracles [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2010-02-01 14:30 (5616 d 16:39 ago) – Posting: # 4677
Views: 24,454

Großer Meister,

❝ Contrary to HS' opinion, I think this is exactly how that sentence should be interpreted for now. I would not be surprised if a slight revision is due soon which addresses this issue and/or the fixed factor problem.


I can't believe that :no:! We have only one study! And shall treat them as if we had some independent 2×2 studies?

What if we have period effects? In the '2×2 extracted evaluation' we are then mixing periods (for instance in T1T2R for the pair T1/R T1 comes from period 1, in sequence T2T1R from period 2).

And what about sequences? For the above example T1T2R and T2T1R are the same in evaluating T1/R?

And what about the error (MSE). In the 3×3 cross-over we have then two (distinct) MSE's and also CV's?

Questions over questions. With the simple answer: This is statistically not so very sound, to be political correct (and not saying nonsense).

Hopefully this will be cleared before the magic 10-Aug-2010.

Regarding the fixed effects issue you questioned above in your post:
I can't imagine, what this means at all :ponder:, especially if I think about the sequence test. Shall we use the error term as the denominator as is in a fully fixed effects model?
We all know that this is the wrong (already Grizzle in his basic paper noticed the right denominator is the subject(sequence) MS).

Hopefully this will be clarified before the magic 10-Aug-2010.


JE Grizzle
The two-period change over design and its use in clinical trials
Biometrics 21, 467-480 (1965)
[Helmut]

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,675 registered users;
32 visitors (0 registered, 32 guests [including 6 identified bots]).
Forum time: 08:09 CEST (Europe/Vienna)

Philosophy, like medicine, has plenty of drugs, few good remedies,
and hardly any specific cures.    Sebastien-Roch Nicolas de Chamfort

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5